A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
A phase 3 trial of Zanubrutinib and Tislelizumab in advanced solid tumours, run by BeOne Medicines, active and no longer recruiting.
Overview
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib is a phase 3 interventional study registered as NCT04170283 by BeOne Medicines, with 955 participants enrolled, started 2020-01-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanubrutinib and Tislelizumab.
Similar pages
not linked directly; found by shared links- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Shares Tislelizumab, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study of SKB518 in Patients With Lung Cancer
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.